Organon Acquired by Sun Pharmaceutical Industries | Healthcare M&A Deal

Sun Pharmaceutical Industries has acquired Organon, a pharmaceuticals business in the US, for $11.75 billion. Sun Pharmaceutical Industries acquisitions target Organon & Co, a US-listed pharma company focused on women’s health and biosimilars with operations across 140 countries. The Sun Pharma strategy for healthcare M&A is to expand its global footprint and strengthen its product portfolio in women’s health and innovative medicines, with integration expected to support revenue growth to about $12.4 billion. The merger acquisition is structured as an all-cash purchase of all outstanding Organon shares at $14 per share, subject to regulatory clearances and shareholder approval. Boards have signed the definitive agreement, with expected close in early 2027 as a strategic acquisition by a strategic buyer.